Inactivation of tumor suppressor p53 results in loss of the apoptosis-regulating function of the p53 protein in tumor cells. Restoration of wild-type p53 expression in p53 mutant tumor cells increases tumor susceptibility to CTL-mediated cytolysis. However, the direct role of p53 in regulating tumor sensitivity to NK cell-mediated lysis and the functional relationship between p53 and granzymes in the control of tumor killing are still poorly documented. In this study, we found that p53 can sensitize tumor-killing susceptibility to NK and granzyme K-mediated cytolysis. Granzyme K is constitutively expressed in high levels in NK cells and induces rapid caspase-independent cell death. Granzyme K may exert a critical role in NK cell-mediated tumor clearance. p53 associates with granzyme K and is a physiological substrate of granzyme K. p53 was processed to three cleavage products of p40, p35, and p13 fragments at Lys 24 and Lys 305 . These three cleavage products harbor strong proapoptotic activities that amplify the proapoptotic action of p53 to potentiate tumor-killing sensitivity. Therefore, p53 is as a cytotoxic bomb that can be triggered by granzyme K, leading to potentiating killing efficacy.
T he tumor suppressor p53 plays multiple roles in cell cycle control, differentiation, angiogenesis, genomic stability, and apoptosis (1) . Mutations of the p53 gene are frequently found in Ͼ50% of all human tumors, suggesting that loss of this gene represents an important step in the formation of human cancers. p53-deficient mice are extremely susceptible to spontaneous, oncogene, and mutation-induced tumorigenesis (2) . Moreover, the ability of p53 to control the cell cycle and apoptosis has been reported to contribute to drug sensitivity induced by many anticancer agents (3) . It is well established that tumor suppressor p53 plays a critical role in tumorigenesis.
Transformed cells still need to escape immune surveillance to form tumor cells. Cytotoxic lymphocytes such as NK and CTL can recognize and eliminate the transformed cells mainly through the granule exocytosis pathway, which releases perforin and tumor killer granzymes (Gzms) 3 from the preformed secretory granules into the immunological synapse formed with the target tumor cell (4 -6). Thiery et al. (7) reported that the restoration of wild-type p53 expression in p53 mutant tumor cells increases tumor susceptibility to CTL-mediated cytolysis (7) . They further showed that p53 is a key determinant in antitumor CTL response that regulates induction of Fas receptor expression, cellular FLICE/caspase 8 inhibitory protein short-form degradation, and Bid translocation to target mitochondria (8) . CTL targeting results in p53 accumulation and activation at very early times (9) . However, the functional relationship is less defined between p53 and Gzms in the control of tumor-killing susceptibility.
GzmK is a second tryptase among all of the Gzms. Tryptase activity is essential for CTL-mediated tumor clearance. GzmK constitutively expresses high levels in CD56 NK cells, memory CD8 T cells, and CD56 T cells (10) . We found that GzmK triggers rapid cell death with ssDNA nicks independently of caspase activation through targeting the endoplasmic reticulum-associated SET protein complex (11, 12) . GzmK can also induce rapid reactive oxygen species (ROS) generation and collapse of mitochondrial inner membrane potential leading to release of cytochrome c and endonuclease G (13) . GzmK-mediated target cell death is consistent with the lysis dynamics of NK cells. It suggests that GzmK exerts an important role in NK cell-mediated tumor clearance. In this study, we found that p53 can sensitize tumor-killing susceptibility to GzmK or NK cell-mediated cytolysis. p53 associates with GzmK and is a physiological substrate of GzmK. p53 was processed to three cleavage products at Lys 24 and Lys 305 . These three cleavage products harbor strong proapoptotic activities that amplify the proapoptotic action of p53 to potentiate tumor-killing sensitivity.
Materials and Methods

Cell lines, Abs, and reagents
HCT116 p53
ϩ/ϩ cells and the isogenic HCT116 p53 Ϫ/Ϫ cells (provided by Dr. B. Vogelstein, Johns Hopkins Medical School, Baltimore, MD) were maintained in McCoy's 5A medium supplemented with 10%FBS. NK cells isolated from PBMC were cultured in DMEM containing 15% FBS, 15% horse serum, 2 mM L-glutamine, and 100 U/ml recombinant human IL-2. H1299 cells (Chinese Academy of Medical Sciences, Beijing, China) were grown in RPMI 1640 medium supplemented with 10% FBS. HeLa and 293A cells were grown in DMEM supplemented with 10% FBS, 50 M 2-ME, 100 U/ml penicillin, and streptomycin. Monoclonal and polyclonal Abs for GzmK were generated by our laboratory. Commercial Abs were mouse mAb against hemagglutinin (HA) (BD Pharmingen), ␤-actin, HRPconjugated sheep anti-mouse IgG (Santa Cruz Biotechnology), and Alexa Fluor 488-conjugated donkey anti-mouse IgG (Molecular Probes). Bax and p53 Abs (DO1, FL393) were purchased from Santa Cruz Biotechnology. LipofectamineTM2000 was from Invitrogen. Annexin V-FITC was from BD Pharmingen and the ProLong Antifade kit was from Molecular Probes. 51 Cr (as sodium dichromate) was purchased from PerkinElmer.
Isolation of NK cells
PBMC from healthy donors were purchased from the Beijing Blood Center and were purified by Ficoll-Hypaque gradient centrifugation separation. Primary NK cells were enriched from PBMC by positive selection using the human NK cell isolation kit according to the manufacturer's instructions. Briefly, the PBMC were resuspended in PBS buffer containing 0.5% BSA and exposed to anti-CD56 microbeads at 4°C for 15 min. NK cells were then positively selected using the MACS cell separator system (Miltenyi Biotec). The purity of the enriched human NK cells was Ͼ90% NK cells as determined by flow cytometry. These enriched human primary NK cells were cultured in IL-2-containing medium.
Pull-down assay
Mutated GzmK (mGzmK) was covalently linked to Affi-Gel 10 (Bio-Rad) according to the manufacturer's instructions. Equal amounts of Affi-Gel 10 beads coupled to GST protein were used as controls in the assays. HCT116 p53 ϩ/ϩ cell lysates were incubated with immobilized mGzmK Affi-Gel 10 overnight at 4°C. The gel was washed four times by brief centrifugation and aspiration. The pull-down proteins separated by SDS-PAGE were analyzed by Western blotting.
Recombinant protein expression
Recombinant GzmK and mGzmK (enzymatically inactive GzmK produced by mutating the active site Ser 214 to alanine) were produced and purified as previously described. Full-length cDNA coding wild-type human p53 and mutant human p53 (K24A, K305A) was subcloned into pQE30 and expressed in Escherichia coli strain M15. Recombinant p53 with 6ϫ His tags were purified through nickel columns as above. The Stratagene QuikChange site-directed mutagenesis kit was used to mutate candidate lysine residues to identify the GzmK cleavage site according to the manufacturer's instructions.
Coimmunoprecipitation and immunoblotting
Abs were preincubated with protein A-Sepharose (Pharmacia) for 1 h at 4°C. Ab-coated beads were washed twice in PBS before being added to recombinant proteins (50 g/ml) or cytosolic lysates (5 ϫ 10 6 cell equivalents in 20 l of Nonidet P-40 lysis buffer) that had been preincubated at 4°C for 2 h. After overnight incubation with shaking at 4°C, the beads were washed extensively in 1% Nonidet P-40/0.1% SDS in PBS and boiled in 2ϫ SDS loading buffer before electrophoresis through SDS-PAGE gels. After transfer to nitrocellulose, blots were probed with the indicated Abs.
Cell-mediated cytotoxicity assay
Tumor cell lysis by NK cells was quantitated in a 4-h 51 Cr release assay. Target cells (1 ϫ 10 6 ) were labeled with 200 Ci of 51 Cr and plated at 1 ϫ 10 4 cells/well. Effector cells were added at various E:T ratios, and after 4 h of incubation, the supernatant was removed and radioactivity was measured in a gamma counter. The percent cytotoxicity was determined as follows: percent cytotoxicity ϭ [(sample release Ϫ spontaneous release)/ (maximum release Ϫ spontaneous release)] ϫ 100. Maximum release of target cells was measured following treatment with 2% Triton X-100 detergent. For selective inhibition of the perforin/Gzm pathway, NK cells were pretreated for 2 h with 500 nM concentrations of concanamycin A (CMA) and then assayed for cytotoxicity.
Loading GzmK with adenovirus
Cells were washed three times in HBSS and resuspended in loading buffer (HBSS with 0.5 mg of BSA/ ml, 1 mM CaCl 2 , and 1 mM MgCl 2 ). Target cells (2 ϫ 10 5 ) in 50 l of loading buffer were incubated at 37°C for the indicated times with different concentrations of GzmK, Ser-Ala Gzmk (SAGzmK), and an optimal dose of adenovirus (Ad). Cells were incubated for an additional 15 min in 1 mM PMSF before being lysed for immunoblot.
Cleavage assay
Cell lysates prepared from HCT116 cells treated with Nonidet P-40 lysis buffer (0.5% Nonidet P-40/25 mM KCl/5 mM MgCl 2 /1 mM PMSF/10 mM Tris-HCl, pH 7.6). Cell lysates (equivalent to 2 ϫ 10 5 cells) or 1 M rp53 was incubated with the indicated doses of GzmK or S-AGzmK for the indicated time points in 20 l of cleavage buffer (50 mM Tris-HCl (pH 7.5), 1 mM CaCl 2 , and 1 mM MgCl 2 ). For in vivo cleavage assay, cells loaded with GzmK/Ad were lysed in 0.5% Nonidet P-40 lysis buffer. The reaction samples were terminated in 5ϫ SDS loading buffer and probed by immunoblotting. For in vitro cleavage assay, 0.5 M rp53 was incubated with different concentrations of GzmK for the indicated times. The reaction products were probed as above.
Flow cytometry analysis
FITC-conjugated annexin V was used to evaluate phosphatidylserine externalization. Target cells treated with S-AGzmK, GzmK, and Ad were stained with annexin V-Fluos and propidium iodide (PI) and analyzed by flow cytometry using a FACSCalibur (BD Biosciences).
TUNEL assay
The TUNEL assay was performed using the In Situ Cell Death Detection Kit (Roche Applied Science) according to the manufacturer's instructions. Briefly, treated tumor cells were washed three times with PBS, fixed with 2% paraformaldehyde in PBS for 1 h at room temperature (RT), and permeabilized with freshly prepared 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice. Fifty microliters of TUNEL reaction mixture was added into each sample and incubated for 1 h at 37°C in a humidified atmosphere in the dark. Cells were further incubated with 5 g/ml Hoechst 33342 (Sigma-Aldrich) in PBS for 10 min and visualized through immunofluorescent microscopy.
Transfection of HCT116 (p53 Ϫ/Ϫ ) and H1299 (p53 Ϫ/Ϫ ) cells with p53
A full-length p53 DNA construct was synthesized by PCR amplification of PQE-30-p53 and inserted into a pEF PGKpuro or pcDNA3.1 plasmid vector. After verifying DNA sequence and orientation, the p53 construct was transfected into HCT116 or H1299 cells using the Lipofectamine 2000 transfection reagent (Invitrogen). The transfectants were selected in the presence of 2 g/ml puromycin or 1 mg/ml G418, and the surviving clones were pooled. The expression of p53 protein in the stable transfectants was confirmed by Western blotting analysis.
Laser-scanning confocal microscopy
HeLa cells were plated on 8-well chamber slides coated with rat collagen I (BD Falcon) and transfected with full-length p53 or p53 fragment plasmids. After a 24-h transfection, cells were incubated with 500 nM MitoTracker (Molecular Probes) for 30 min according to the manufacturer's instruction. The cells were fixed with 4% paraformaldehyde for 20 min at RT and permeabilized with 0.1% Triton X-100 for another 20 min. The cells were incubated at RT for 1 h with 5 g/ml anti-HA mAb, 50 g/ml donkey serum, and 100 g/ml RNase I. The cells were stained with Alexa Fluor 488-conjugated donkey anti-mouse IgG and soaked for 5 min in PBS containing 0.1 g/ml Hoechst. The slides were mounted with ProLong Antifade reagent and observed using laser-scanning confocal microscopy (Olympus FV500 microscope).
Plasmids and luciferase assay
Human wild-type p53 encoding pCMV-HA plasmid with an N-terminal influenza HA epitope tag was used to generate different p53 fragments. Different p53 fragments were cloned in pCMV-HA in-frame with HA tag. Luciferase assays were performed following the instructions of the Promega Dual Glo kit. Briefly, 293A cells were cotransfected with p53 or p53 fragment expression vector (pCMV-HA-p53, pCMV-HA-p40, pCMV-HAp35, pCMV-HA-p13) with promoters (PG13-Luc, Bax-Luc, P21-Luc, MDM2-Luc). Luciferase assay was performed after a 36-h transfection. Cells were harvested and washed once with PBS. Then, they were lysed in a lysis buffer. Luciferase activity was measured in 20 l of the supernatants using a dual luciferase reporter assay system (14) .
Results
GzmK associates with p53
We previously showed that GzmK induces caspase-independent cell death with ssDNA nicking. GzmK proteolyses the nucleosome assembly protein SET and abolishes its nucleosome assembly activity (12) . GzmK activates the DNase NM23H1 activity to nick chromosomal DNA via cleavage of its inhibitor SET. To define the substrates of GzmK, enzymatic inactive S-AGzmK(mGzmK) was generated to perform a pull-down assay by using p53-expressed colon cancer cell (HCT116p53 ϩ/ϩ ) lysates. p53 was eluted from immobilized mGzmK Affi-Gel 10 beads and coeluted with a previously identified GzmK substrate SET (Fig. 1A) . GST Affi-Gel beads did not precipitate p53 or SET. To verify the direct interaction of p53 with GzmK, we performed coimmunoprecipitation experiments with the rp53 and S-AGzmK. Anti-p53 Ab can precipitate mGzmK (Fig. 1B) . Anti-GzmK Ab was also capable of precipitating rp53. Neither anti-GST Ab or control Ig precipitated mGzmK or rp53. rGST had no interaction with either mGzmK or rp53. The interaction of mGzmK with native p53 was confirmed through preincubation of mGzmK with HCT116p53 ϩ/ϩ cell lysates as shown in Fig. 1B . Therefore, GzmK directly binds to p53 in vitro and associates with native p53 in vivo.
Gzm K cleaves p53 at Lys 24 and Lys 305
To determine whether p53 is cleaved by GzmK, rp53 was incubated with different doses of GzmK at 37°C for 90 min or with 0.1 M GzmK for 5-90 min. p53 began to degrade at a low concentration of 20 nM GzmK or an early time of 5 min ( Fig.  2A) . The major p40 band was detected by the DO1 anti-p53 Ab. The inactive S-AGzmK cannot cleave rp53. p53 degradation required enzymatic activity of GzmK. To test the cleavage sites of p53, rp53 was treated with active GzmK and resolved by SDS-PAGE followed by Coomassie staining. rp53 was processed to two major bands, p40 and p35. Cleavage sites were determined at Lys 24 and Lys 305 through mass spectrometry and site-directed mutagenesis. We mutated Lys 24 to alanine (K24A) or both Lys 24 and Lys 305 to alanine (K24A/K305A) and expressed their recombinant proteins. These two mutant proteins were treated with active GzmK and visualized by SDS-PAGE. K24A mutant only produced one product, p40 fragment (Fig.  2B) . Although K24A/K305A cannot be cleaved by GzmK, these data further confirmed p53 was directly processed by GzmK at Lys 24 and Lys 305 . Therefore, three cleavage products were generated as p40(1-305), p35(25-305), and p13(306 -393). However, the p13 fragment was undetectable. It may be in a low concentration or further degradation by GzmK.
p53 is a physiological substrate of GzmK but not GzmB
To look at whether GzmK can proteolyse native p53, HCT116 p53 ϩ/ϩ cell lysates (2 ϫ 10 5 equivalent) were incubated with 50 -300 nM GzmK or with 0.1 M GzmK for 5-90 min. Native p53 started to be processed at an early time of 5 min and at a low dose of 50 nM GzmK (Fig. 3A) . After 20 min or 200 nM GzmK, p53 was almost completely proteolysed. The same blot was stripped and probed by ␤-actin. ␤-Actin was unchanged as a good control. Similar results were obtained by using another p53-contained human lung adenocarcinoma epithelial cell line A549 cells (Fig. 3B) . To further verify p53 processing is physiologically relevant, HCT116 p53 ϩ/ϩ cells were treated with 1 M GzmK in the presence of Ad for 1-4 h. p53 was cleaved by 2 h and probed by the DO1 anti-p53 Ab (Fig. 3C) . The cleavage product p40 was detectable as that of GzmK-processed rp53 or cell lysate p53. SET was cut to produce a 25-kDa product as a previous observation. ␤-Actin was unchanged as a good loading control. Treating cells with either GzmK or Ad alone or with mutant GzmK plus Ad did not result in the change of p53 (Fig.  3C) . Two hundred nanomolar GzmK started to cleave p53, which is earlier than SET cleavage. We demonstrated here that p53 cannot be cleaved by GzmB (Fig. 3D) . Caspase 3 was activated in GzmB-loaded cells, but not in GzmK-loaded cells. Taken together, p53 is a physiological substrate of GzmK, but not GzmB.
p53 cleavage products exert proapoptotic activity
To evaluate whether the p53 processed products have proapoptotic function, we generated expression vectors containing either fulllength p53 or the various fragments with N-terminal HA tags as (Fig. 4B) . After a 24-h transfection, the cells were deprived of serum for another 24-h incubation to initiate apoptosis. Surprisingly, p40, p35, and p13 showed spherical morphology, floating, and other death features through observation by phase-contrast microscopy, which were reminiscent of the full-length p53 (Fig. 4C) . pCMV-HA-transfected cells were used as a negative control. Then dead cells were stained by PI and followed by flow cytometry. The PI-positive cells for the three fragments were 57.9 Ϯ 3% for p40, 44.6 Ϯ 4% for p35, and 50.5 Ϯ 1% for p13. The PI-positive cells for p53 were 65.3 Ϯ 3%. HA control was 12.9 Ϯ 2%. Together, all three cleavage products have strong proapoptotic activity.
Cellular localization and transcriptional activity of GzmK-processed p53 fragments
We assessed cellular distribution of the p53 cleavage products through confocal microscopy. Full-length p53 and p13 (306 -393), which harbor the nuclear localization sequence, exhibited a predominant nuclear staining (Fig. 5A ). p40 (1-305) and p35 (25-305) were distributed to the cytoplasm and nucleus. Both of them are localized to mitochondria. All three GzmK processed products induce cell death as described above. We next tested whether their proapoptotic activity depends on their transcriptional action. We analyzed several p53 target promoters such as p21, PG13, Bax, and MDM2 genes through a luciferase reporter assay. p40 showed strong transcriptional action to p21, PG13, and MDM2 (Fig. 5B) . Whereas it exhibited weak transcriptional activity to Bax. p35 harbored weak transcriptional activity to all of the detected genes. p13 had no transcriptional action. Puma was only weakly expressed in p53-or p40-transfected H1299 cells (Fig. 5C ).
p53 sensitizes GzmK-mediated tumor cell death
To determine in vivo effect of p53 on GzmK-mediated killing, To confirm the role of p53 in potentiating GzmK-induced lysis, HCT116p53
Ϫ/Ϫ cells were expressed with wild-type p53 through the pEF-PGK-p53 vector. p53 stable transfectants were screened out and p53 expression was probed with anti-p53 Ab (Fig. 6C) .
p53-rescued HCT116p53
Ϫ/Ϫ cells were incubated with GzmK plus Ad at 37°C for 4 h and followed by TUNEL assay. p53-rescued tumor cells gained more TUNEL-positive cells than their parental p53-deficient cells (48.6 Ϯ 2% vs 29.1 Ϯ 3%, p Ͻ 0.05; Fig. 6, D and E) . The death rate was similar to that of HCT116p53 ϩ/ϩ cells (48.6 Ϯ 2% vs 51.5 Ϯ 2%, p Ͻ 0.05). To verify the effect of p53 on GzmK-mediated cell death, an additional p53-deficient human lung cancer cell line H1299 was transfected with pcDNA3.1-p53 vector. p53 stable expression transfectants were screened out through G418 selection (Fig. 6F) . A, HeLa cells were plated in chambers and transfected with p53 or p53 fragments. After a 24-h transfection, the cells were fixed, permeabilized, and probed with HA Ab. MitoTracker was used to probe mitochondria and the nucleus was stained with Hoechst. B, The transcriptional activity of fulllength p53 and three fragments was assayed through activation of Bax, p21, MDM2, or PG13 promoters. 293A cells were cotransfected with p53 or p53 fragment expression vectors (pCMV-HA-p53, pCMV-HA-p40, pCMV-HA-p35, or pCMV-HA-p13) with the luciferase-tagged promoters. Luciferase assay was performed after a 36-h transfection. The results represent at least three independent experiments and are calculated as mean Ϯ SD. C, Puma was weakly expressed in the cells transfected with p53 and p40 fragments. p53-deficient H1299 cells were cotransfected with p53 or p53 fragment expression vectors as above. Puma, Bax, and Bid were analyzed by immunoblotting. ␤-Actin was probed as a loading control.
FIGURE 6. p53 sensitizes tumor cells to GzmK-induced cell death. A and B, HCT116 p53
Ϫ/Ϫ and HCT116 p53 ϩ/ϩ cells were treated with 1 M GzmK or S-AGzmK for 4 h in the presence of Ad (100 PFU/ml) at 37°C (A) or the indicated times with 1 M GzmK plus Ad (B). The treated cells were stained with annexin V/PI followed by flow cytometry. The data are representative of at least four separate experiments. Total cell death including annexin V and PI as well as double-positive cells were calculated as shown in the right panels (mean Ϯ SD). C, p53 was restored in HCT116 p53
Ϫ/Ϫ cells. HCT116 p53 Ϫ/Ϫ cells were transfected with p53 expression vectors (pEF-p53/puromycin). The stable transfectants were selected and verified by immunoblotting. D, Rescue of p53 restores the sensitivity of HCT116 p53 Ϫ/Ϫ cells to GzmK-induced death. HCT116 p53 Ϫ/Ϫ , HCT116 p53 ϩ/ϩ , and HCT116 p53 Ϫ/Ϫ cells transfected with p53 (rescue) were incubated with 1 M GzmK and Ad at 37°C for 4 h and assessed for apoptosis by TUNEL assay. E, TUNEL-positive cells were calculated as shown in the mean Ϯ SD for three independent experiments. F, p53-deficient H1299 cells (p53 Ϫ/Ϫ ) were transfected with p53 expression vectors (pcDNA3.1-p53/neomycin). p53-expressed stable transfectants were selected with G418 and verified by Western blotting. G, H1299 (p53 Ϫ/Ϫ ) and H1299 (p53 ϩ/ϩ ) cells were treated with 1 M GzmK or mutant S-AGzmK for 4 h in the presence of Ad (100 PFU/ml) at 37°C. The treated cells were stained with annexin V/PI followed by flow cytometry. The data are representative of at least three separate experiments and calculated as mean Ϯ SD.
p53-expressed H1299 cells were much more sensitive to GzmKinduced cytolysis than p53-deficient H1299 cells (45.4 Ϯ 2% vs 28.1 Ϯ 2%, p Ͻ 0.01; Fig. 6G ). The data are representative of at least three separate experiments.
p53 potentiates tumor-killing susceptibility to NK cytolysis
We previously showed that GzmK induces a rapid target cell death, which is consistent with the dynamics of NK cell-mediated tumor lysis. To investigate physiological function of p53 to tumor-killing susceptibility, IL-2-activated CD56 NK cells were incubated with HCT116p53 ϩ/ϩ or HCT116p53 Ϫ/Ϫ cells followed by a 4-h
51
Cr release assay. NK cells exhibited good killing action to HCT116p53 ϩ/ϩ cells even at a low E:T ratio, 2.5 (Fig. 7A) . CMA, an inhibitor of cytotoxic granule exocytosis through chelating free calcium, can block NK cell-mediated cytolysis. It suggests that NK cell-mediated killing is mainly induced by the perforin/Gzm pathway. p53-deficient HCT116p53 Ϫ/Ϫ cells were more resistant to NK cell-mediated lysis (Fig. 7B) . p53-restored HCT116 p53 Ϫ/Ϫ cells (rescue) were more sensitive to cytolysis induced by NK cells similar to HCT116p53 ϩ/ϩ cells (Fig. 7B) . Similar results were found in p53-rescued H1299 cells (Fig. 7C) . Taken together, p53 sensitizes tumor lysis susceptibility to NK cells.
Discussion
p53 tumor suppressor has a major function in transducing stress to the apoptotic machinery of the cell, consistent with the role of p53 status as a determinant of cellular response to DNA-damaging drugs (3, 15) . Inactivation of p53 has been identified in Ͼ50% tumor types and such inactivation will result in loss of the apoptosis-regulating function of the p53 protein. It is well established that p53 mediates tumor growth suppression through cell cycle arrest and apoptosis regulation. Considering the high mutation frequency of p53 in tumor cells, it is believed that p53 has the potential ability to regulate the tumor cell susceptibility to immune killer cells. The role of p53 in the control of tumor susceptibility to CTL-mediated lysis has been reported. Recently, Chouaib's group (7, 8) found that p53 sensitizes tumor susceptibility to CTL killing. However, the direct role of p53 in regulating tumor sensitivity to NK-mediated lysis and the functional relationship between p53 and Gzms in the control of tumor killing are still poorly documented. In this study, we demonstrated that p53 can sensitize tumor killing to NK cytolysis and GzmK-mediated cell death. p53 was processed by GzmK to three cleavage products of p40, p35, and p13, which exerted strong proapoptotic activity to augment cell lysis.
NK cells and CTL are the principal cytotoxic effectors of the antitumor immune response. They kill tumor cells by two major pathways that require direct cellular contact. The first pathway is granule exocytosis, which delivers a membrane-disrupting molecule perforin (pore-forming protein) and proapoptotic serine proteases Gzms. The second one is involved in death receptor-induced surface expression of ligands on killer cells, which cross-links the corresponding receptors of target cells such as Fas ligand and TRAIL and TNFR (16) . In our study, we found that the cytotoxic granules exocytosis inhibitor CMA can block NK-induced tumor lysis. It indicates that NK-mediated cytotoxicity is induced by the perforin/Gzm pathway. Our observation is in agreement with CTLmediated tumor elimination (9) .
NK cells are named initially due to their ability to spontaneously kill certain tumor cells in vitro. They are commonly defined as the effectors of the innate immune system, acting as the first line of defense against viral infection and transformed cells (17) . GzmK is highly expressed in NK cells (10, 18) . We previously demonstrated that GzmK induces rapid target cell death independent of caspase activation (12) . GzmK can target the SET complex to degrade its substrates, releasing the NM23H1 DNase activity to induce ssDNA nicks. GzmK also triggers rapid ROS generation and collapse of mitochondrial inner membrane potential (13) . Blockade of ROS accumulation suppresses GzmK-induced cell death. Intracellular ROS accumulation is believed to be a key initial step in caspase-dependent apoptosis, including that induced by GzmB and GzmM, and caspaseindependent apoptosis that is mediated by GzmA and GzmK (11, 19 -22) . A recent report showed stress-induced ROS generation initiates a strong p53 activation (23). Meslin et al. (9) just reported that targeting tumor cells by CTL induces p53 accumulation at early times. This observation is consistent with the dynamics of ROS stress induced by CTL. These data suggest that p53 plays a key role in granule-mediated cytolysis. We showed here that HCT116 p53 ϩ/ϩ cells are more cytotoxic to NK-and GzmK-induced death than their parental p53-deficient HCT116 p53
Ϫ/Ϫ cells. p53-rescued HCT116 p53
Ϫ/Ϫ cells restore their sensitivity to GzmK-induced cytolysis. We shed light on the molecular mechanism of p53 to potentiate tumor cell susceptibility through NK-mediated cytolysis. We found that p53 is a physiological substrate of GzmK and is processed at Lys 24 and Lys 305 to generate three cleavage fragments (p40, p35, p13). All three of these products exert proapoptotic activity that amplifies the proapoptotic action of p53. p40 and p35 showed a similar distribution pattern in cells and translocated into mitochondria. The p40 fragment without the C terminus of p53 harbor higher transcriptional activity. The last 30 residues of p53 constitute a negative regulatory domain with potent suppression of sequence-specific DNA binding by p53 and transactivation of target genes (24) . Deletion of the C terminus by GzmK activates transactivation of target gene expression in transfected cells, which correlated with up-regulation of p21, PG13, and MDM2, three known targets of p53. Our observation is in agreement with an earlier report that showed p53(‚C30) upregulates expression of p21 (24 -26) . However, p40 showed weak transcriptional activity to Bax that remains to be further studied. The p35 fragment has potent proapoptotic activity. Although the transcriptional activity of p35 was lower than the p40 fragment, these data suggest that the N terminus may interact with cellular transcriptional elements and be required for transactivation of p53 target genes. A recent report showed caspase 3-processed p53 fragments p53(1-186), p53 , and p53(22-393) were localized to mitochondria and caused mitochondrial depolarization (27) . Therefore, p40 and p35 might target mitochondria to cause death. We also found that the C-terminal 13-kDa domain localized to the nucleus and bore overt proapoptotic activity. Fine's group (28) reported that the C-terminal peptide can induce target necrosis in multiple mutated p53 human prostate cancer cells. However, p13 had not any transcriptional activity. Thus, proapoptotic activity of GzmK-processed p53 products requires further investigation.
Different types of DNA damage can induce p53 cleavage products. Damaged DNA induces N-terminal cleavage of p53 to generate p50(‚N23) and p35(core) protein products (24) . The cleaved p53 products exert important roles in cell cycle arrest and apoptosis induction. GzmK induces ssDNA nicks. Whether this DNA damage can enhance p53 processing by GzmK as a positive feedback loop needs to be studied further. p53 can be processed to form various fragments by caspases to amplify the process of apoptosis (27) . A previous study showed that p63, a p53 homolog, is a caspase target, and such cleavage results in loss of the transcriptional inhibitor domain at the C terminus of the p63a isoform (29). Melino's group (30) recently reported that p73, a member of the p53 family, is cleaved by caspase 3 and caspase 8 in vitro and in vivo during apoptosis elicited by DNAdamaging drugs and TRAIL receptor ligation. Our observation indicates that p53 is as a cytotoxic bomb that can be triggered by GzmK, leading to potentiating killing efficacy. Therefore, restoration of p53 function in tumor cells might be a potential strategy for cancer immunotherapy by enhancing killing sensitivity of killer lymphocytes.
